3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
22
Carcinoma, Hepatocellular
15
Small Cell Lung Carcinoma
11
Triple Negative Breast Neoplasms
9
Neoplasms
8
Colorectal Neoplasms
6
Breast Neoplasms
6
Urinary Bladder Neoplasms
5
Lung Neoplasms
5
Carcinoma, Renal Cell
5
Ovarian Neoplasms
4
Carcinoma, Transitional Cell
3
Carcinoma
3
Uterine Cervical Neoplasms
2
Prostatic Neoplasms
2
Melanoma
2
Colonic Neoplasms
2
Venous Thrombosis
1
Urologic Neoplasms
1
Stomach Neoplasms
1
Squamous Non-Small Cell Lung Cancer
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Diseases
1
Rectal Neoplasms
1
Radiation Pneumonitis
1
Prostatic Neoplasms, Castration-Resistant
1
Peritoneal Neoplasms
1
Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer
1
Non-Squamous Non-Small Cell Lung Cancer
1
Non-Small-Cell Lung
1
Interventions
Cisplatin
21
Radiotherapy
16
Fluorouracil
16
Paclitaxel
15
Irinotecan
8
Docetaxel
8
Neoadjuvant Therapy
6
Drug Therapy
5
tislelizumab
4
sintilimab
4
Surgical Procedures, Operative
4
Radiation
4
Oxaliplatin
4
Leucovorin
4
Esophagectomy
4
Capecitabine
4
toripalimab
3
pembrolizumab
3
TP protocol
3
Chemotherapy, Adjuvant
3
S 1 (combination)
2
Levoleucovorin
2
Injections
2
Cetuximab
2
Carboplatin
2
lenvatinib
1
irinotecan sucrosofate
1
durvalumab
1
atropine sulfate-diphenoxylate hydrochloride drug combination
1
atezolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Esophageal Squamous Cell Carcinoma
×
atezolizumab
×
Clear all
NCT04543617
2026-04-17
SKYSCRAPER-07
Hoffmann-La Roche
Phase 3
Active not recruiting
760 enrolled